Overview

NICE is unable to make a recommendation about the use in the NHS of bimekizumab (Bimzelx) for treating moderate to severe hidradenitis suppurativa in adults. This is because UCB Pharma withdrew from the appraisal.

Last reviewed: 15 January 2025

Next review: We will review this decision if the company decides to make an evidence submission.

Guidance development process

How we develop NICE technology appraisal guidance